Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis
Related Posts
Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan[...]
Deleija JD, Shah SZ, Felzer J, Tan X, Garvey C, DeCato TW, Pennington K, Sehgal S, Kennedy C, Kumar A. Pulmonary Rehabilitation Referral Practice Patterns[...]
Krishan S, Agarwal S, Munir MB, Ajijola O, Yang EH, Deswal A, Torbey E, Cheng R, Asad ZUA. Cardiovascular Outcomes in Patients With Cancer Undergoing[...]